ARS Pharmaceuticals cut 2026 cash-based operating expenses to about $248 million, signaling tighter cost controls while prioritizing commercial investments. Florida Medicaid added Neffy to its unrestricted formulary effective July 1, 2026, expanding payer access, though no new commercial formulary wins were announced in the July cycle. The company remains on track for cash-flow breakeven in 2027, but SPRY stock fell about 26% as investors weighed limited near-term formulary progress against cost controls and an ongoing CVS coverage debate.
ARS Pharmaceuticals (SPRY) is slated to announce its first-quarter earnings on May 15, with analysts predicting a loss of 54 cents per share and a revenue of $22.12 million, a significant increase from last year's $7.97 million. Additionally, a recent leadership change with Donn Casale appointed as president could signal strategy shifts impacting future performance.
SPRY shares rose 18.86% following negative news for competitor AQST. FDA cited deficiencies in AQST's Anaphylm NDA, delaying market competition. ARS seeks to strengthen neffy's position amid AQST's regulatory issues. Analyst report highlights SPRY's potential as a market leader. ARS's funding status supports the anticipated launch of neffy.
ALK secures exclusive rights to Neffy nasal spray in selected markets. Neffy has FDA approval for emergency allergic reactions and plans in Canada. ALK estimates peak sales potential for Neffy at $430 million in licensed territories. ARS Pharma anticipates up to $465 million from ALK for Neffy milestone payments. William Blair expects strong demand and a solid launch for Neffy through 2025.
FDA approved ARS Pharmaceuticals’ Neffy for emergency allergic reactions. Cantor Fitzgerald initiated coverage with an Overweight rating and $30 price target. Neffy expected to capture 30% market share in allergy practices. Peak sales for Neffy projected to exceed $1.2 billion by 2031. SPRY stock has shown a slight increase of 1.17% recently.
